Financial Review: Whitehawk Therapeutics (WHWK) versus Its Competitors

Whitehawk Therapeutics (NASDAQ:WHWK) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its competitors? We will compare Whitehawk Therapeutics to similar businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Whitehawk Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
Whitehawk Therapeutics Competitors	4783	9955	15978	370	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 88.15%. Given Whitehawk Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics has less favorable growth aspects than its competitors.

Risk and Volatility

Whitehawk Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics’ competitors have a beta of 10.31, meaning that their average share price is 931% more volatile than the S&P 500.

Institutional and Insider Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Whitehawk Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-75.99%	-68.57%
Whitehawk Therapeutics Competitors	-2,625.49%	-359.63%	-43.39%

Earnings and Valuation

This table compares Whitehawk Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	-$63.69 million	-36.83
Whitehawk Therapeutics Competitors	$437.67 million	-$68.90 million	-9.41

Whitehawk Therapeutics’ competitors have higher revenue, but lower earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Whitehawk Therapeutics competitors beat Whitehawk Therapeutics on 8 of the 13 factors compared.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.